Contact the Editorial Desk

Editorial correspondence

This desk welcomes corrections to the record: a citation that's been quoted imprecisely, a new study that updates one of the four pages, or a regulatory change that shifts an approval status. The most useful notes name three things, which page, the exact passage, and a supporting source (a DOI or PubMed ID where you have one), so a proposed change can be checked against its source before anything is updated.

Editorial mailbox: editors@whatisapeptide.com

What this desk can't help with

Because whatisapeptide.com reports on peptide research rather than practicing medicine or selling anything, it can't weigh in on whether any peptide covered here is right for a particular person, name a dose or schedule, help source or verify a research-chemical product, or offer any form of medical guidance. Semaglutide is a prescription medicine available only through a licensed provider; BPC-157, GHK-Cu, and KPV are unapproved research chemicals with no established human dosing at all. Anyone with a medical question should bring it to a licensed clinician in their own jurisdiction. Replies to this mailbox aren't guaranteed and may take a while.